Cyphellophora guyanensis (n ‫؍‬ 15), other Cyphellophora species (n ‫؍‬ 11), Phialophora europaea (n ‫؍‬ 43), and other Phialophora species (n ‫؍‬ 12) were tested in vitro against nine antifungal drugs. The MIC 90 s across all of the strains (n ‫؍‬ 81) were, in increasing order, as follows: posaconazole, 0.063 g/ml; itraconazole, 0.5 g/ml; voriconazole, 1 g/ml; micafungin, 1 g/ml; terbinafine, 2 g/ml; isavuconazole, 4 g/ml; caspofungin, 4 g/ml; fluconazole, 8 g/ml; amphotericin B, 16 g/ml.
A lthough dermatophytes and yeasts account for the majority of superficial and cutaneous fungal infections, members of the black yeast-like fungi are reported regularly (2, 18) . Humid indoor environments such as bathrooms and swimming pools (14, 15) are potential reservoirs for black yeast infections. Cyphellophora and Phialophora species are black yeast-like fungi that form a phylogenetic "europaea clade" within the order Chaetothyriales (9) and are recovered from human skin and nails (8, 18) . Phialophora europaea was found in 27% of positive cultures with black yeasts (18) which are found simultaneously with dermatophytes on the skin of diabetic patients (11) . The taxonomy of the genus Cyphellophora has recently been revised, and 11 independent species were recognized in the "europaea clade," i.e., Cyphellophora laciniata, C. vermispora, C. pluriseptata, C. suttonii, C. fusarioides, C. pauciseptata, C. guyanensis, Phialophora ambigua, P. oxyspora, P. reptans, and P. europaea (9, 12) . Cyphellophora laciniata, C. pluriseptata (5, 10) , C. pauciseptata, and P. ambigua thus far have been isolated exclusively from superficial lesions in human infections (7, 9, 12) , while C. fusarioides originated from bronchoalveolar lavage fluid from a patient after heart bypass surgery (19) . Cyphellophora suttonii was originally isolated from a phaeohyphomycotic lesion in a dog's ear (1) but also from ulcerating skin lesions in a patient with sarcoidosis (17) . At present, there is no information available on the antifungal susceptibility profiles of Cyphellophora and its relatives. This study aimed to determine the in vitro susceptibilities of a large collection of clinical and environmental isolates of Cyphellophora and Phialophora species belonging to the black yeast "europaea clade" to eight antifungal drugs and isavuconazole (13, 20, 21) , a new triazole that currently is undergoing phase III clinical trials.
A total of 81 strains were obtained from the Centraalbureau voor Schimmelcultures (CBS; Utrecht, The Netherlands) Fungal Biodiversity Centre, which included Cyphellophora guyanensis (n ϭ 15), C. laciniata (n ϭ 3), C. pauciseptata (n ϭ 1), C. pluriseptata (n ϭ 3), Cyphellophora suttonii (n ϭ 1), C. vermispora (n ϭ 3), Phialophora ambigua (n ϭ 1), P. europaea (n ϭ 43), P. oxyspora (n ϭ 3), and P. reptans (n ϭ 8) (see Table S1 in the supplemental material). The strains were obtained from human (n ϭ 55) and animal (n ϭ 1) clinical samples, environmental samples (n ϭ 12), plant materials (n ϭ 11), and unknown sources (n ϭ 2). The set included all available ex-type strains of the species described and was supplemented with newly isolated strains. In addition to genotyping, species identity was confirmed by molecular characterization of the internal transcribed spacer region, the partial DNA-dependent RNA polymerase II largest-subunit gene, the beta-tubulin gene, and the nuclear large-subunit rRNA gene (9, 12) . Antifungal susceptibility testing was performed as described in CLSI document M38-A2, with some modifications (6) . Briefly, isolates were cultured on potato dextrose agar in the dark (25°C) for up to 7 days to induce sporulation. Inocula were prepared by scraping the surface of the fungal colonies with a cotton swab moistened with sterile physiological saline containing 0.05% Tween 40. Large particles were allowed to settle for 5 min, and then a suspension of spores was adjusted with a spectrophotometer (Spectronic 20D; Milton Roy, Rochester, NY) to 68 to 71% transmission (at 530 nm) and diluted 10-fold to yield a final inoculum of 1.5 ϫ 10 4 to 5 ϫ 10 4 CFU/ml. The test concentrations of amphotericin B (Bristol-Myers Squibb, Woerden, The Netherlands), itraconazole (Janssen Research Foundation, Beerse, Belgium), voriconazole (Pfizer Central Research, Sandwich, United Kingdom), posaconazole (Schering-Plough, Kenilworth, NJ), isavuconazole (Basilea Pharmaceutica International AG, Basel, Switzerland), and terbinafine (Novartis Pharma, Basel, Switzerland) ranged from 0.016 to 16 g/ml; those of fluconazole (Pfizer) ranged from 0.063 to 64 g/ml; and those of caspofungin (MSD, Haarlem, The Netherlands) and micafungin (Astellas Pharma, Ibaraki, Japan) ranged from 0.008 to 8 g/ml. After 72 h of incubation at 25°C, MICs and minimum effective concentrations Table  S2 in the supplemental material). All of the strains of Cyphellophora and Phialophora tested had low MICs of itraconazole, voriconazole, posaconazole, and micafungin, while most of the strains had high MICs of fluconazole and amphotericin B. The highest geometric mean MICs were 27.6 g/ml of fluconazole, followed by 4 g/ml of amphotericin B, and much lower geometric mean MICs of the triazoles, echinocandins, and allylamine (isavuconazole, 1.9 g/ml; caspofungin, 1.1 g/ml; voriconazole, 0.3 g/ml; terbinafine, 0.3 g/ml; itraconazole, 0.1 g/ml; micafungin, 0.07 g/ml; posaconazole, 0.03 g/ml). Posaconazole was the drug with the best overall activity. (Table 1 ). In general, the MIC 90 s of itraconazole, voriconazole, and isavuconazole were at least 2 log 2 dilution steps higher than those of posaconazole. The environmental isolates of C. guyanensis had higher MICs of terbinafine and isavuconazole than the clinical strains of P. europaea. The two echinocandins showed marked differences in their MECs; in most cases, micafungin had potent activity, with a geometric mean MEC and MEC 90 showing at least 2 log 2 dilution steps higher activity than caspofungin. These data are in agreement with previously reported findings on the black yeasts Cladophialophora (3), Fonsecaea (16) , and Rhinocladiella (4). There was a significant difference (P Ͻ 0.001) between the MICs of the eight antifungals for P. europaea (group E), P. reptans (group D), and C. guyanenesis (group B) ( Table 1) . Phialophora europaea isolates, when divided into skin and nail subgroups, showed no difference in susceptibility (see Table S2 in the supplemental material). The present paper provides the first antifungal susceptibility data on clinical species of Cyphellophora and its relatives in the genus Phialophora, which compose a phylogenetic "europaea clade" within the order Chaetothyriales. The results suggest that the species in this clade of black yeast-like organisms are susceptible in vitro to the newer azoles and to micafungin; however, these in vitro data still need to be complemented by clinical confirmation in vivo.
